UnknownNot applicableNCT00317408
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
- Principal Investigator
- Alfred Reiter, MDUniversity Hospital Erlangen
- Intervention
- anti-thymocyte globulin(biological)
- Enrollment
- 96 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2004
Study locations (30)
- St. Anna Children's Hospital, Vienna, Austria
- U.Z. Gasthuisberg, Leuven, Belgium
- University Hospital Brno, Brno, Czechia
- Charles University Hospital, Prague, Czechia
- Centre Leon Berard, Lyon, France
- Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
- Klinikum Augsburg, Augsburg, Germany
- Helios Klinikum Berlin, Berlin, Germany
- Charite University Hospital - Campus Virchow Klinikum, Berlin, Germany
- Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
- Kinderklinik der Universitaet Bonn, Bonn, Germany
- Staedtisches Klinikum - Howedestrase, Braunschweig, Germany
- Klinikum Bremen-Mitte, Bremen, Germany
- Klinikum Chemnitz gGmbH, Chemnitz, Germany
- Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00317408 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation